Cagent Vascular develops endovascular devices that combine serration remodeling therapy (SRT) with intravascular lithotripsy (IVL) to treat calcified peripheral and coronary arterial disease. Its Serranator portfolio has been used in over 40,000 procedures and is sold across most major U.S. markets and in select international markets. The company recently reported first human-use cases of its Serranator SONIC IVL System within the REMODEL I prospective, multicenter study. Cagent plans to advance the technology through a global REMODEL II pivotal trial and to commercialize the SONIC IVL System in peripheral arteries while developing a coronary artery platform. The company is headquartered in Wayne, Pa.

Total raised

$107M

Funding rounds

5

Latest round

Series D

Latest activity

May 2026